NCT06553209CompletedPhase 1
Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
A Randomized, Double-blind, Single/Multiple Dose Escalation, Placebo-controlled Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM512 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 22 Sept 2025
Brief summary (registry, in English)
This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and patients with moderate to severe atopic dermatitis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 110 (actual)
- First submitted
- 11 Aug 2024
- Start date
- 2 Sept 2024
- Primary completion date
- 26 Aug 2025
- Lead sponsor
- Keymed Biosciences Co.Ltd
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06553209
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 110
- From 2 Sept 2024 to the primary completion date, 26 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have participated in any clinical trials of drugs or medical devices within 3 months before the screening.
- Have severe infections, severe injuries, or undergone major surgical procedures within 3 months before screening.
- Have lost more than 400 mL of blood due to blood donation or other reasons within 3 months before screening.
- Positive drug abuse test or positive alcohol breath test result.
Who the study is looking for
- Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
- Body mass index (BMI) ranges from 18.0 to 26.0 kg/m2 (including boundary values).
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital of Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.